Vertex Pharmaceuticals (VRTX) Financials, Dividends & Stock Info
Explore comprehensive financial data for Vertex Pharmaceuticals, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (572 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Vertex Pharmaceuticals (VRTX) is a biotechnology company. The company reports annual revenue of $11.7B and net income of $3.7B. Its profit margin is 31.4%.
Vertex Pharmaceuticals Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Vertex Pharmaceuticals Financial Health ScoreFY2025
Strong financial position with minor areas to watch
+48 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Vertex Pharmaceuticals Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Mar 17, 2026
Revenue Breakdown (FY2024)
See Vertex Pharmaceuticals detailed breakdown →About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Above-Average Marginsvs 14.8% sector median / 21.8% avg
Generates $21.2 in profit for every $100 of shareholder equity. Higher than 60% in Health Care.
vs 18.1% sector median / 15.0% avg
Keeps 31 cents of every dollar in revenue as profit. Higher than 77% in Health Care.
8th consecutive year of revenue growth.
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin 109% above sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Mar 17, 2026
Vertex Pharmaceuticals 10-Year Revenue, Profit & Cash Flow History
Net income reached a record high of $4.0B in FY2025.
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0B(+8.9%) | $11.0B(+11.7%) | $9.9B(+10.5%) | $8.9B(+17.9%) | $7.6B(+22.1%) | $6.2B(+49.1%) | $4.2B(+36.6%) | $3.0B(+326.4%) | $714.7M(-58.0%) | $1.7B(+64.9%) |
| Net Income | $4.0B(+838.1%) | $-535,600,000(-114.8%) | $3.6B(+9.0%) | $3.3B(+41.8%) | $2.3B(-13.6%) | $2.7B(+130.4%) | $1.2B(-43.9%) | $2.1B(+695.8%) | $263.5M(+335.1%) | $-112,052,000(+79.9%) |
| Total Assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B | $11.8B | $8.3B | $6.2B | $3.5B | $2.9B |
| Total Debt | - | - | - | - | - | - | - | - | - | - |
| Total Equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B | $8.7B | $6.1B | $4.4B | $2.0B | $1.2B |
| Profit Margin | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 36.9% | -6.6% |
| ROE | 21.2% | -3.3% | 20.6% | 23.9% | 23.2% | 31.2% | 19.3% | 47.3% | 13.0% | -9.7% |
| ROA | 15.4% | -2.4% | 15.9% | 18.3% | 17.4% | 23.1% | 14.1% | 33.6% | 7.4% | -3.9% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B | $8.1B | $5.3B | $2.7B | $7.4B | $4.9B | $2.4B | $6.6B |
| Net Income | $646.3M | $-1,448,600,000 | $-2,494,000,000 | $1.1B | $2.7B | $1.6B | $699.8M | $2.5B |
| Total Assets | $25.6B | $22.5B | $22.5B | $22.5B | $22.7B | $22.7B | $22.7B | $18.2B |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Vertex Pharmaceuticals Free Cash Flow & Dividend Coverage
Generates approximately $9M in free cash flow per day.
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $236.1M | $844.9M | $1.3B | $1.6B | $3.3B | $2.6B | $4.1B | $3.5B | -$492.6M | $3.6B |
| CapEx | -$56.6M | -$99.4M | -$95.4M | -$75.4M | -$259.8M | -$235.0M | -$204.7M | -$200.4M | -$297.7M | -$437.6M |
| Free Cash Flow | $179.5M | $745.5M | $1.2B | $1.5B | $3.0B | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
| FCF Margin | 10.5% | 104.3% | 38.6% | 35.9% | 48.2% | 31.8% | 44.0% | 33.8% | -7.2% | 26.6% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Mar 17, 2026
Vertex Pharmaceuticals Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for VRTX.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Vertex Pharmaceuticals FAQ
What is Vertex Pharmaceuticals's annual revenue?
Vertex Pharmaceuticals (VRTX) reported $11.7 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Vertex Pharmaceuticals profitable?
Yes, Vertex Pharmaceuticals is profitable with a 31.4% net profit margin and $3.7 billion in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Vertex Pharmaceuticals pay dividends?
No, Vertex Pharmaceuticals (VRTX) does not currently pay dividends to shareholders.
What is Vertex Pharmaceuticals's financial health score?
Vertex Pharmaceuticals has a financial health score of 84/100 (Grade: A), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Vertex Pharmaceuticals financial data are available?
10 years of financial data are available for Vertex Pharmaceuticals from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.